In 2016, the U.S. Food and Drug Administration (FDA) approved Spinraza (nusinersen), the first drug for SMA, a modified antisense oligonucleotide that acts on the expression of the SMN2 gene, leading to the production of a full-length SMN2 transcript [17]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.